An Open, Multicenter Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies

Completed · Not applicable

Conditions studied: Herpes Simplex, HIV Infections

In brief

To evaluate the safety and efficacy of intermittent intravenous (IV) foscarnet in the treatment of acyclovir-resistant herpes simplex virus (HSV) infections in AIDS patients and other immunocompromised patients. To evaluate the necessity, efficacy, and safety of IV maintenance foscarnet therapy in preventing recurrent disease. To confirm the pharmacokinetics of intermittent induction and maintenance IV regimens.

Key facts

Study ID

NCT00002272

Run by

Astra USA

Last updated by the study team

2005-06-24

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Concurrent Medication:
• Allowed:
• Cyclosporine.
• Patients must have AIDS as defined by the CDC, or be patients with other immunocompromised states (transplant patients; other hematologic malignancies with recognized cell-mediated immune deficiency), and have herpes simplex virus (HSV) infection documented by culture and in vitro resistance to acyclovir by standard laboratory susceptibility or suspected resistance to acyclovir after an acyclovir treatment failure in which acyclovir was administered for at least 2 weeks intravenously at doses of 30 mg/kg/day (or a comparative dose adjusted for renal insufficiency). In vitro susceptibility data must be pending in the latter case.
• Patients must be able to give informed consent.
• Patients < 18 years of age may participate with the consent of parent, guardian, or person with power of attorney, or through the provisions of state laws regarding emancipated minors.
• Expected survival of at least 6 months.
• Prior Medication:
• Allowed:
• Cyclosporine.
• Ganciclovir.

You may not qualify if…

• Co-existing Condition:
• Patients with the following are excluded:
• Known allergy to foscarnet.
• Any clinically significant pulmonary or neurologic impairment (e.g., patients who are intubated or comatose).
• Concurrent Medication:
• Excluded:
• Any potentially nephrotoxic agent (except cyclosporine).
• Immunomodulators.
• Biologic response modifiers.
• Investigational agents.
• Patients with the following are excluded:
• Known allergy to foscarnet.
• Any clinically significant pulmonary or neurologic impairment (e.g., patients who are intubated or comatose).
• Prior Medication:
• Excluded within 7 days of entry:
• Any potentially nephrotoxic agent (except cyclosporine).
• Excluded within 14 days of entry:
• Immunomodulators.
• Biologic response modifiers.
• Investigational agents.

Where it is running

• Foscarnet Research Program / Park Plaza Hosp — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.